Login Register Cart 0
Generic placeholder image

Current Nanomedicine

Editor-in-Chief

ISSN (Print): 2468-1873
ISSN (Online): 2468-1881

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

DoE Enabled Development and In-Vitro Optimization of Curcumin-tagged Cilostazol Solid Nano Dispersion

Author(s): Aruna Rawat, Vikas Jhawat* and Rohit Dutt

Volume 13, Issue 2, 2023

Published on: 15 August, 2023

Page: [113 - 131] Pages: 19

DOI: 10.2174/2468187313666230719121457

Price: $65

Abstract

Background: Diabetes is a prevailing disease worldwide and its complications are also hazardous including nephropathy. Drug available to treat Diabetic Nephropathy (DN) faces bioavailability issues related to solubility and absorption of drugs. Cilostazol (CLT) is a BCS class II drug that is poorly water-soluble which affects its therapeutic efficacy. CLT reduces reactive oxygen species (ROS) increased in DN. Curcumin (Cur) is also hydrophobic but Cur has many therapeutic efficacies like anti-inflammatory and antioxidant properties that help for the treatment of DN.

Objective: The objective of the current study was to develop and optimize the Cilostazol Solid Dispersion Nanoparticle (SDN) to improve the bioavailability of the drug by tagging it with Cur by using PVP VA S 630 as polymer and Poloxamer 407 as surfactant.

Method: Different formulations were developed using the emulsion solvent evaporation method, PVP VA S 630 as the hydrophilic polymer, and Poloxamer 407 as a surfactant. Two-factor, threelevel Box-Behnken Design (BBD) was used for statistical analysis of the selected process variable's main effect and interactive effect on the response. Curcumin tagging was also done for the entire batches. Nanoparticles were characterized by FT-IR spectroscopy, DSC, Particle size, Zeta potential, Drug entrapment efficiency, Solubility, and % CDR studies.

Results: Among the 17 different formulations (CLT1-CLT 17), with a solubility of 39.5 μg/ml, a % CDR of 99.55, a typical particle size of 219.67 nm with a PDI of 0.258, entrapment efficiency of 73.47%, and a -10.6 mV of Zeta potential, CLT-15 was optimized. To determine CLT and curcumin, the simultaneous UV calibration method was created. Overall, the DSC study indicated the amorphous nature of the Nano Dispersion, which in turn means the successful entrapment of the CLT in the Nano Dispersion matrix. TEM images also confirmed the spherical nanoparticles. The optimized batch of drugs tagged with curcumin was compared with the plain drug Solid Dispersion Nanoparticles.

Conclusion: Together with the molecules of curcumin, the solid nano dispersion of CLT was produced, which will add to the benefits of the management of Diabetic Nephropathy. In the current study, we underline the importance of utilising both API and phytochemicals in the treatment of Diabetic Nephropathy, and we anticipate further basic research or clinical trials to support innovative treatments. It is possible to use these matrix-forming polymers for active ingredients with poor solubility, whether they are natural or synthetic. It has also been demonstrated that these carriers (PVP VA S 630 & Poloxamer) increase the dissolution rate (in-vitro).

« Previous Next »
Graphical Abstract

[1]
Kaushik R, Budhwar V, Kaushik D. An overview on recent patents and technologies on solid dispersion. Recent Pat Drug Deliv Formul 2019; 1-13.
[PMID: 31951172]
[2]
Lipinski C. Poor aqueous solubility: an industry wide problem in drug discovery. Am Pharm Rev 2002; 1-16.
[3]
Minocha S, Pahwa S, Arora V. SOlubility enhancement of poorly water soluble drugs by various techniques. J Biomed Pharma Res 2019; pp. 13-9.
[4]
Jermain SV, Brough C, Williams RO. Amorphous solid dispersions and nanocrystal technologies for poorly water-soluble drug delivery:An Update. Int J Pharm 2017; 1-63.
[PMID: 29128423]
[5]
Zhang S, Sun Y, Zhou L, Jiang Z, Yang X, Feng Y. Osmotic pump tablets with solid dispersions synergized by hydrophilic polymers and mesoporous silica improve in vitro/in vivo performance of cilostazol. Int J Pharm 2020; 588: 119759.
[http://dx.doi.org/10.1016/j.ijpharm.2020.119759] [PMID: 32800938]
[6]
Sawicki E, Schellens JHM, Beijnen JH, Nuijen B. Inventory of oral anticancer agents: Pharmaceutical formulation aspects with focus on the solid dispersion technique. Cancer Treat Rev 2016; 50: 247-63.
[http://dx.doi.org/10.1016/j.ctrv.2016.09.012] [PMID: 27776286]
[7]
Sonal Mazumder AkD, Naresh pavurala. Enhanced dissolution of poorly soluble antiviral drugs from nanoparticles of cellulose acetate-based solid dispersion matrices. Asian j pharmaceutical sciences 2017; 532-41.
[8]
Nadia Saffoon RU, Huda NH, Sutradhar KB. Enhancement of oral bioavailability and solid dispersion: A review. J Appl Pharm Sci 2011; 13-20.
[9]
Rawat A, Verma S, Kaul M, Saini S. Formulation, evaluation and optimization of solid dispersion of glipizide using face centered central composite design. Int J Pharm Pharm Sci 2011; 475-82.
[10]
Andrews GP, Qian K, Jacobs E, Jones DS, Tian Y. High drug loading nanosized amorphous solid dispersion (NASD) with enhanced in vitro solubility and permeability: Benchmarking conventional ASD. Int J Pharm 2023; 632: 122551.
[http://dx.doi.org/10.1016/j.ijpharm.2022.122551] [PMID: 36581107]
[11]
Bhujbal SV, Mitrab B nemr U, et al. Pharmaceutical amorphous solid dispersion: A review of manufacturing strategies. Acta Pharm 2021; 11(8): 2505-36.
[12]
Murdande SB, Pikal MJ, Shanker RM, Bogner RH. Solubility advantage of amorphous pharmaceuticals: I. A Thermodynamic analysis. J Pharm Sci 2010; 99(3): 1254-64.
[13]
Jog R, Burgess DJ. Pharmaceutical amorphous nanoparticles. J Pharm Sci 2016; 1-27.
[PMID: 27816266]
[14]
Araki K, Yoshizumi M, Kimura S, et al. Application of a microreactor to pharmaceutical manufacturing: Preparation of amorphous curcumin nanoparticles and controlling the crystallinity of curcumin nanoparticles by ultrasonic treatment. AAPS PharmSciTech 2020; 21(1): 17.
[http://dx.doi.org/10.1208/s12249-019-1418-8] [PMID: 31811523]
[15]
Maity SL, Chakraborti S. Formulation, physicochemical characterization and antidiabetic potential of naringenin-loaded poly D, L lactide-co-glycolide (N-PLGA) nanoparticles. Eur Polym J 2020; 1-10.
[16]
Umerska A, Gaucher C, Oyarzun-Ampuero F, Fries-Raeth I. Polymeric nanoparticles for increasing oral bioavailability of curcumin. Antioxidants 2018; 4(4): 46.
[17]
Robyn J, Tapp GD, Shaw JE, et al. Albuminuria is evident in the early stages of diabetes onset: Results from the australian diabetes, obesity, and lifestyle study. Am J Kidney Dis 2004; 792-8.
[18]
Lim AK. Diabetic nephropathy – complications and treatment. Int J Nephrol Renovasc Dis 2021; 361-81.
[19]
Hu Q, Chen Y, deng X, et al. Diabetic nephropathy: Focusing on pathological signals, clinical treatment, and dietary regulation. Biomed Pharmacother 2023; 1-16.
[20]
Frimodt-Møller PRaM. Clinical features and natural course of diabetic nephropathy. diabetic nephropathy. Denmark: Springer International Publishing AG, part of Springer Nature. 2019; pp. 21-32.
[21]
Chen S, Chen L, Jiang H. Integrated bioinformatics and clinical correlation analysis of key genes, pathways, and potential therapeutic agents related to diabetic nephropathy. Hindawi-Disease Markers 2022; 2022: 9204201.
[22]
Mohamed AF, Sayed HM, Zaki HF, Safar MM. Modulation of toll-like receptor 4/nuclear factor-kappa b, nuclear factor erythroid 2-related factor 2/hemeoxygenase-1, and phosphoinositide 3-kinase/akt signaling by cilostazol mitigates lipopolysaccharide-induced septic acute kidney injury. Bull Fac Pharm Cairo Univ 2023; 60(2): 1-13.
[23]
Lichao G, Qiang L, Yujie W, et al. Research on mechanism of curcumin with chitosan nanoparticles in regulating the activity of podocytes in diabetic nephropathy through alleviating oxidative stress and inflammation. Sci Adv Mater 2022; 14(4): 752-9.
[http://dx.doi.org/10.1166/sam.2022.4249]
[24]
Chopra H, Dey PS, Das D, et al. Curcumin nanoparticles as promising therapeutic agents for drug targets. Molecules 2021; 26(16): 4998.
[http://dx.doi.org/10.3390/molecules26164998] [PMID: 34443593]
[25]
Dagar N, Das P, Bisht P, Taraphdar AK, Velayutham R, Arumugam S. Diabetic nephropathy: A twisted thread to unravel. Life Sci 2021; 278: 119635.
[http://dx.doi.org/10.1016/j.lfs.2021.119635] [PMID: 34015285]
[26]
Tiwari RK, Pandey RK, Shukla SS. A review on mechanism and plants used for diabetic nephropathy: A curse of diabetes. Mintage J Pharmaceutical & Medical Sciences 2019; pp. 5-13.
[27]
Tsabang N, Yedjou CG, Tsambang L, et al. Treatment of diabetes and/or hypertension using medicinal plants in cameroon. Med Aromat Plants 2015; (2): 1-15.
[PMID: 26550547]
[28]
Patel RUV. Spectrophtometric methods for simultaneous estimation of telmisartan and cilostazol in synthetic mixture. AN I J PHARMA SCI 2015; pp. 276-91.
[29]
Damor D, Mittal K, Patel B, Mashru R. Method development and validation of simultaneous estimation of cilostazol and telmisartan. Research & Reviews. J Pharm Anal 2015; 4(3): 41-8.
[30]
Gaikwad A, Shelar MU, Kadam J, Andhale G, Singh S. Development and validation of simultaneous uv-spectrophotometric method for the determination of resveratrol and piperine in pharmaceutical dosage form. J Pharm Negat Results 2022; 13(8): 4141-50.
[31]
Fan S, Nedev H, Vijayan R, Iorga BI, Beckstein O. Precise force-field-based calculations of octanol-water partition coefficients for the SAMPL7 molecules. J Comput Aided Mol Des 2021; 35(7): 853-70.
[http://dx.doi.org/10.1007/s10822-021-00407-4] [PMID: 34232435]
[32]
Jin GH. Role of surfactant micellization for enhanced dissolution of poorly water-soluble cilostazol using poloxamer 407-based solid dispersion via the anti-solvent method. MDPI Pharmaceutics. 2021; pp. 1-14.
[33]
Dong W, Su X, Xu M, Hu M, Sun Y, Zhang P. Preparation, characterization, and in vitro/vivo evaluation of polymer-assisting formulation of atorvastatin calcium based on solid dispersion technique. Asian J Pharmaceutical Sciences 2018; pp. 546-54.
[34]
Yang R, Zhang GGZ, Zemlyanov DY, Purohit HS, Taylor LS. Release mechanisms of amorphous solid dispersions: Role of drug-polymer phase separation and morphology. J Pharm Sci 2023; 112(1): 304-17.
[http://dx.doi.org/10.1016/j.xphs.2022.10.021] [PMID: 36306863]
[35]
Priyadarsini M, Avula PR. Quality by design approach for development of amorphous solid dispersions of efavirenz by melt-quench technique. Nat Volatiles & Essent Oils 2022; 9(3): 43-59.
[36]
Ryu S, Park S, Lee HY, Lee H, Cho CW, Baek JS. Biodegradable nanoparticles-loaded plga microcapsule for the enhanced encapsulation efficiency and controlled release of hydrophilic drug. Int J Mol Sci 2021; 22(6): 2792.
[http://dx.doi.org/10.3390/ijms22062792] [PMID: 33801871]
[37]
Kumar A, Sandhya S, Kar NR, Sahoo S, Behera MP, Shaw RK. Nanoparticulate system of novel taxane derivatives as in-vitro evaluation and characterization. J Clinical Otorhinolaryngology 2023; 27(1): 859-71.
[38]
Nagai N, Yoshioka C, Ito Y, Funakami Y, Nishikawa H, Kawabata A. Intravenous administration of cilostazol nanoparticles ameliorates acute ischemic stroke in a cerebral ischemia/reperfusion-induced injury model. Int J Mol Sci 2015; 16(12): 29329-44.
[http://dx.doi.org/10.3390/ijms161226166] [PMID: 26690139]
[39]
Aghrbi I, Fülöp V, Jakab G, Kállai-Szabó N, Balogh E, Antal I. Nanosuspension with improved saturated solubility and dissolution rate of cilostazol and effect of solidification on stability. J Drug Deliv Sci Technol 2021; 61: 102165.
[http://dx.doi.org/10.1016/j.jddst.2020.102165]
[40]
Jakubowska E, Milanowski B, Lulek J. A systematic approach to the development of cilostazol nanosuspension by liquid antisolvent precipitation (lasp) and its combination with ultrasound. Int J Mol Sci 2021; 22(22): 12406.
[http://dx.doi.org/10.3390/ijms222212406] [PMID: 34830298]
[41]
Guner G, Amjad A, Berrios M, Kannan M, Bilgili E. Nanoseeded desupersaturation and dissolution tests for elucidating supersaturation maintenance in amorphous solid dispersions. Pharmaceutics 2023; 15(2): 450.
[http://dx.doi.org/10.3390/pharmaceutics15020450] [PMID: 36839772]
[42]
Rudraraj SV. Disintegration mediated controlled release supersaturating solid dispersion formulation of an insoluble drug: Design, development, optimization, and in vitro evaluation. AAPS PharmSciTech 2014; 1-13.
[PMID: 25190361]
[43]
Sawafta O, Alhadid S, Abu Awwad IA, Migdadi E, Aljaberi A. Impact of the manufacturing technique on the dissolution-enhancement functionality of PEG4000 in Cilostazol tablets. Pharmacia 2021; 68(1): 243-50.
[http://dx.doi.org/10.3897/pharmacia.68.e62465]
[44]
Nemr AA. EL-MAHROUK GM, EL-MAHROUK HA. Development and evaluation of surfactant-based elastic vesicular system for transdermal delivery of Cilostazole: ex-vivo permeation and histopathological evaluation studies. J Liposome Res 2021; 1-14.
[45]
Sedik AA, Amer AA. Modulatory effects of cilostazol; an nrf2/ho-1 activator against nafld in rats confirmed by molecular docking and ftir studies. Egypt J Chem 2022; 65(12): 493-508.
[46]
Karan T, Erenler R, Bozer BM. Synthesis and characterization of silver nanoparticles using curcumin: Cytotoxic, apoptotic, and necrotic effects on various cell lines. De Gruyeter 2022; 77(7-8c): 243-350.
[47]
Baas J, Senninger N, Elser H. The reticuloendothelial system. An overview of function, pathology, and recent methods of measurement. Z Gastroenterol 1994; 32(2): 117-23.
[PMID: 8165827]
[48]
Lu M, Yin N, Liu W, Cui X, Chen S, Wang E. Curcumin ameliorates diabetic nephropathy by suppressing nlrp3 inflammasome signaling. Biomed Research Inernational. 2017; p. 1-11.
[49]
Terife G, Wang P, Faridi N, Gogos CG. Hot melt mixing and foaming of soluplus® and indomethacin. Polym Eng Sci 2012; 52(8): 1629-39.
[http://dx.doi.org/10.1002/pen.23106]
[50]
Elvina M, Butar-Butar T, Wathoni N, Rathi H, Wardhan YG. Solid dispersion technology for improving the solubility of antiviral drugs. Pharmaceutical Sciences and Research 2023; 10(1): 1-19.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy